Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. decided not to leave it up to a jury to calculate the amount of damages they would have to pay for their at-risk launch of generic Protonix (pantoprazole) and instead reached a $2.15 billion settlement with Pfizer Inc.
Under the agreement Teva will pay $1.6 billion and Sun $550 million to Pfizer and , which owns the Protonix patent and provided an exclusive license to Pfizer subsidiary Wyeth for U.S. marketing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?